Abstract: The invention relates to a selenium compound. Said selenium compound has formula (I), where R1=alkyl; R2=H, R4C(=0), R4OC(=0), a-aminoacyl, CH3SeCH2CH2CH(NH2)C(=0), CH3SeCH2CH2CH(OH)C(=0); X=OH, OR3, NH2, NR4R5, ?-amino acid, CH3SeCH2CH2CH(COOH)NH—, CH3SeCH2CH2CH(COOH)0-; R3=alkyl; R4=alkyl, aryl; R5=H, alkyl, aryl; R4 and R5 which can together form a 5- or 6-membered cycloalkyl radical which can comprise a heteroatom; provided that when X=NH-terbutyl, R2?C(=0)CH3. Said compound can be used as a pharmaceutical substance, in particular as an antitumour substance.

Abstract: The invention relates to a selenium compound. Said selenium compound has formula (I), where R1=alkyl; R2=H, R4C(=0), R4OC(=0), a-aminoacyl, CH3SeCH2CH2CH(NH2)C(=0), CH3SeCH2CH2CH(OH)C(=0); X=OH, OR3, NH2, NR4R5, ?-amino acid, CH3SeCH2CH2CH(COOH)NH—, CH3SeCH2CH2CH(COOH)0-; R3=alkyl; R4=alkyl, aryl; R5=H, alkyl, aryl; R4 and R5 which can together form a 5- or 6-membered cycloalkyl radical which can comprise a heteroatom; provided that when X=NH-terbutyl, R2?C(=0)CH3. Said compound can be used as a pharmaceutical substance, in particular as an antitumour substance.

Abstract: Pharmaceutical/cosmetic compositions containing a dermatologically effective amount of hyaluronic acid, at least one retinoid and/or salt and/or derivative thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, formulated into a physiologically acceptable medium therefor, are useful for the treatment of wrinkles, fine lines, fibroblast depletions and scars.

Abstract: Pharmaceutical/cosmetic compositions containing a dermatologically effective amount of hyaluronic acid, at least one retinoid and/or salt and/or derivative thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, formulated into a physiologically acceptable medium therefor, are useful for the treatment of wrinkles, fine lines, fibroblast depletions and scars.

Abstract: The invention relates to the enrichment of non-photosynthetic micro-organisms with organic selenium, and more particularly with selenomethionine, from a compound of the seleno-hydroxyacid type such as 2-hydroxy-4-methylseleno-butanoic acid in the (D, L) form or in the form of an enantiomer, salt, ester, or amide derivative of said compound, and to the use of micro-organisms, particularly bacteria thus enriched in the fields of animal or human nutrition, cosmetics, or pharmaceuticals.

Abstract: Pharmaceutical/cosmetic compositions containing a dermatologically effective amount of hyaluronic acid, at least one retinoid and/or salt and/or derivative thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, formulated into a physiologically acceptable medium therefor, are useful for the treatment of wrinkles, fine lines, fibroblast depletions and scars.

Abstract: The present invention relates to a novel process for preparing 2-hydroxy-4-methylselenobutyric acid from 3-methylselenoproprion-aldehyde. The 2-hydroxy-4-methylselenobutyric acid is obtained alone or as a mixture with its sulphur-containing analogue. The invention also relates to the compositions, in particular nutritional compositions, comprising a mixture of 2-hydroxy-4-methylselenobutyric acid and 2-hydroxy-4-methylthiobutyric acid, and a physiologically acceptable medium, and to the use of this mixture as a dietary ingredient.

Abstract: The invention relates to a pharmaceutical or cosmetic composition for topical and/or parenteral application comprising, in a physiologically acceptable medium, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation. The invention is of use in particular in human dermatology or in reconstructive surgery.

Abstract: The invention relates to the enrichment of non-photosynthetic micro-organisms with organic selenium, and more particularly with selenomethionine, from a compound of the seleno-hydroxyacid type such as 2-hydroxy-4-methylseleno-butanoic acid in the (D, L) form or in the form of an enantiomer, salt, ester, or amide derivative of said compound, and to the use of micro-organisms, particularly bacteria thus enriched in the fields of animal or human nutrition, cosmetics, or pharmaceuticals.

Abstract: The invention relates to the combination of hyaluronic acid and of at least one hyaluronic acid oligomer constituted of 1 to 2 disaccharide units. The invention is of use in particular in human dermatology or in reconstructive surgery.

Abstract: The invention relates to a combination of hyaluronic acid and of at least one inhibitor of hyaluronic acid degradation, for use in particular in human dermatology or in reconstructive surgery.

Abstract: The invention relates to a pharmaceutical or cosmetic composition for topical and/or parenteral application comprising, in a physiologically acceptable medium, at least one retinoid or salts and derivatives thereof, and at least one inhibitor of hyaluronic acid degradation. The invention is of use in particular in human dermatology or in reconstructive surgery.

Abstract: The invention relates to a pharmaceutical or cosmetic composition for topical and/or parenteral application comprising, in a physiologically acceptable medium, at least one retinoid or salts and derivatives thereof, and at least one hyaluronic acid oligomer chosen from compounds containing from 1 to 6 disaccharide units. The invention is of use in particular in human dermatology or in reconstructive surgery.

Abstract: The present invention relates to a novel process for preparing 2-hydroxy-4-methylselenobutyric acid from 3-methylselenoproprion-aldehyde. The 2-hydroxy-4-methylselenobutyric acid is obtained alone or as a mixture with its sulphur-containing analogue. The invention also relates to the compositions, in particular nutritional compositions, comprising a mixture of 2-hydroxy-4-methylselenobutyric acid and 2-hydroxy-4-methylthiobutyric acid, and a physiologically acceptable medium, and to the use of this mixture as a dietary ingredient.

Abstract: Pharmaceutical/cosmetic compositions containing a dermatologically effective amount of hyaluronic acid, at least one retinoid and/or salt and/or derivative thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, formulated into a physiologically acceptable medium therefor, are useful for the treatment of wrinkles, fine lines, fibroblast depletions and scars.

Abstract: The purpose of this invention is: new selenohydroxy acid compounds and their derivatives; their process for the preparation; use of the new compounds as precursors of L(+)-selenomethionine and/or source of selenium in human or animal nutrition, in cosmetics and pharmaceutics; and nutritional, cosmetic and pharmaceutical compositions containing them.

Abstract: The purpose of this invention is: new selenohydroxy acid compounds and their derivatives; their process for the preparation; use of the said new compounds as precursors of L(+)-selenomethionine and/or source of selenium in human or animal nutrition, in cosmetics and pharmaceutics; and nutritional, cosmetic and pharmaceutical compositions containing them.

Abstract: The invention is directed to novel cyclic organoselenium compounds useful as antioxidants, pharmaceutical compositions containing them, and methods for their preparation.

Abstract: The present invention broadly relates to racemic or optically active 5-substituted 3,4-dihydroxy-2(5H)-furanone compounds and their pharmaceutically acceptable salts, useful for treating a pathology in which reactive oxygen species and inflammatory mediators are contributing deleterious factors, such as acute or chronic inflammatory disorders, for example, asthma, rheumatoid arthritis, inflammatory bowel disease, and acute respiratory distress syndrome; neurodegenerative disorders, such as Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, traumatic brain injury and multiple sclerosis; cardiovascular diseases, such as atherosclerosis; viral diseases, such as AIDS; skin diseases, such as psoriasis, sunburn and premature aging; and eye diseases, such as glaucoma, cataract, senile macular degeneration, inflammatory eye conditions, trauma, post-traumatic eye disorders, diabetic retinopathy, and eye infections.

Abstract: The invention concerns novel benzisoselen-azoline and -azine derivatives. These novel derivatives have the following general formula (II): ##STR1## where: R.sup.1 to R.sup.8 and R.sup.10 have various meanings, in particular H, alkyl, etc . . . ; ##STR2## Y.sup.- represents the anion of a pharmaceutically acceptable anion; n=0, 1; m=0, 1, 2; p=1, 2, 3; q=2, 3, 4; r=0, 1; and their pharmaceutically acceptable salts of acids or bases; there being no more than one substituent R.sup.9 in each molecule with general formula II. These novel derivatives can be used in medication.